Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

Regulatory ApprovalFormycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

at the Promise of Interleukin-2 Therapy Conference, taking place at the Centre International de Conférences Sorbonne Université in Paris, France, from September 4-7, 2024. The Company will ...

Immunotherapy represents a groundbreaking approach to combating various diseases by harnessing and enhancing the body’s ...

Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® received MHRA approval for both subcutaneous and intravenous formulations, to ...

Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent ...

As we increase the number of patients, we remain excited by the outlook for our Phase 1 clinical trial of soquelitinib for ...

Preclinical Portfolio: includes development candidates WTX-712 and WTX-518, our IL-21 and binding protein resistant IL-18 INDUKINE molecules, respectively, for treatment of cancer, and WTX-921, an ...

Presented updated clinical and biomarker activity data at the IOVC in October 2024. Investigators reported ongoing improved ...

CEL-SCI Corporation reported financial results for the fiscal year ended September 30, 2024, as well as key clinical and corporate developments. "We are very optimistic about the prospects of our ...

When monotherapy with oral antidiabetic agents fails, combination therapy with repaglinide plus metformin has been demonstrated to be safe and effective in the treatment of T2DM. Type 2 diabetes ...